Day: March 18, 2021

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Sigilon Therapeutics, Inc. (NASDAQ:SGTX), a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today reported financial results for the fourth quarter and full year ended December 31, 2020 as well as certain other business highlights.“2020 was a transformational period for Sigilon marked by the achievement of numerous key regulatory, clinical, and financial milestones, which we believe have positioned us to deliver on our commitments over the next several years,” commented Rogerio Vivaldi, M.D., Chief Executive Officer of Sigilon. “The modularity of our Shielded Living Therapeutics™ platform has enabled us to build a robust pipeline spanning a diverse range of chronic disorders, including rare blood,...

Reports approximately 82,000 tests in the fourth quarter of 2020Raised $118M gross proceeds in December 2020 from a concurrent secondary equity offering and issuance of convertible notes, and $25M in gross proceeds from a recent private placement with two leading healthcare-focused investment fundsMaintains 2021 revenue guidance rangeManagement will host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. PTSAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today provided corporate updates and reported financial results for the fourth quarter and full-year ended December 31, 2020.Progenity made significant progress during the fourth quarter, both with its revenue generating...

Company Announces $100M Increase in Share Repurchase AuthorizationFourth Quarter Total Net Sales Increase 22.1%Comparable Store Sales Increase 8.8%Diluted EPS Increases 27.3% to $0.98; Adjusted Diluted EPSIncreases 31.1% to $0.97Full-Year Total Net Sales Increase 28.4%Comparable Store Sales Increase 15.6%Diluted EPS Increases 72.0% to $3.68; Adjusted Diluted EPSIncreases 61.2% to $3.16HARRISBURG, Pa., March 18, 2021 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the fourth quarter and full-year fiscal 2020.Fourth Quarter Summary:     Total net sales increased 22.1% to $515.8 million.  Comparable store sales increased 8.8%.The Company opened 4 new stores and closed one location, ending the quarter with 388 stores in 25 states, a year-over-year increase...

RARITAN, N.J., March 18, 2021 (GLOBE NEWSWIRE) — Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world’s largest pure-play in-vitro diagnostics (IVD) companies, today announced financial results for the fourth quarter and fiscal year ended January 3, 2021.Fourth Quarter 2020 Operational Highlights“We continue to see strong momentum in our base business as reflected in our fourth quarter 2020 Core revenue growth of 9%,” said Chris Smith, chairman and chief executive officer, Ortho Clinical Diagnostics. “This was mainly driven by the continued double-digit growth in our integrated instrument installed base, as well as higher volumes in both the Clinical Laboratory and Transfusion Medicine product portfolios. In addition, the company showed great agility by developing and launching the first high throughput COVID-19...

SAN DIEGO, March 18, 2021 (GLOBE NEWSWIRE) — CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced its financial results for the year ended December 31, 2020.Fiscal 2020 and Recent Operating HighlightsRevenue of $24.4 million for fiscal year 2020;Gross margin of 45.1% for fiscal year 2020;Maintained total cash balance of $4.5 million at year end;Total retail distribution increased to more than 7,300 stores as of December 31, 2020, an increase from 5,500 stores as of December 31, 2019;Launched PlusCBDTM brand refresh and new products (Q3);Launched Happy LaneTM, a new THC-free CBD brand and product line for the convenience store channel (Q3);Launched CVTM Acute, a clinically researched wide spectrum proprietary...

HOUSTON, March 18, 2021 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today reported important corporate events and its financial results for the full year and the fourth quarter ended December 31, 2020.“In 2021, we continue to develop our differentiated LSD1 inhibitor, seclidemstat, for the treatment of cancers with high unmet need. During the fourth quarter of 2020 and through early 2021, Salarius achieved two key objectives that are important for the future of the Company: the completion of the dose-escalation stage of the Phase 1/2 Ewing sarcoma trial and the strengthening of our finances,” said David Arthur, President and CEO of Salarius. “As a result, Salarius...

Wide-ranging transformation program completedR&D Day scheduled for April 28, 2021, to provide data updates, and announce strategic priorities and clinical development plan going forward$291.2 million in cash, cash equivalents and marketable securities as of December 31, 2020CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results, including an update on its CD47 clinical programs, for the year ended December 31, 2020. All financial amounts in this news release are in United States dollars, unless otherwise stated.“2020 was a critical year in Trillium’s evolution, as we completed a wide-ranging transformation program spanning all aspects...

DENVER, March 18, 2021 (GLOBE NEWSWIRE) — Extraction Oil & Gas (NASDAQ: XOG) (“Extraction” or the “Company”) today reported financial and operating results for the fourth-quarter and full-year 2020 and provided updated guidance for the full-year 2021.Fourth-Quarter and Full-Year 2020 HighlightsAchieved average net sales volumes of 82,944 barrels of oil equivalent per day (Boe/d), of which 37% was crude oil and 62% total liquids, for the three months ended December 31, 2020. Average net sales volumes for the year ended December 31, 2020, were 88,907 Boe/d, of which 39% was crude oil and 63% total liquids.Emerged from financial restructuring with total debt of $265 million drawn on its $500 million credit facilityEliminated major midstream minimum volume commitments and negotiated new, cost-competitive midstream agreementsAppointed...